Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.

समान संसाधन

• Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
  द्वारा: Costantini, D, और अन्य
  प्रकाशित: (2010)
• (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
  द्वारा: Costantini, D, और अन्य
  प्रकाशित: (2007)
• Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
  द्वारा: McLarty, K, और अन्य
  प्रकाशित: (2009)
• Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
  द्वारा: Costantini, D, और अन्य
  प्रकाशित: (2010)
• 111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
  द्वारा: Cornelissen, B, और अन्य
  प्रकाशित: (2012)